Literature DB >> 21068233

Spatial configuration of hepatitis E virus antigenic domain.

Li Xing1, Joseph C Wang, Tian-Cheng Li, Yasuhiro Yasutomi, James Lara, Yury Khudyakov, Darren Schofield, Suzanne U Emerson, Robert H Purcell, Naokazu Takeda, Tatsuo Miyamura, R Holland Cheng.   

Abstract

Hepatitis E virus (HEV) is a human pathogen that causes acute hepatitis. When an HEV capsid protein containing a 52-amino-acid deletion at the C terminus and a 111-amino-acid deletion at the N terminus is expressed in insect cells, the recombinant HEV capsid protein can self-assemble into a T=1 virus-like particle (VLP) that retains the antigenicity of the native HEV virion. In this study, we used cryoelectron microscopy and image reconstruction to show that anti-HEV monoclonal antibodies bind to the protruding domain of the capsid protein at the lateral side of the spikes. Molecular docking of the HEV VLP crystal structure revealed that Fab224 covered three surface loops of the recombinant truncated second open reading frame (ORF2) protein (PORF2) at the top part of the spike. We also determined the structure of a chimeric HEV VLP and located the inserted B-cell tag, an epitope of 11 amino acids coupled to the C-terminal end of the recombinant ORF2 protein. The binding site of Fab224 appeared to be distinct from the location of the inserted B-cell tag, suggesting that the chimeric VLP could elicit immunity against both HEV and an inserted foreign epitope. Therefore, the T=1 HEV VLP is a novel delivery system for displaying foreign epitopes at the VLP surface in order to induce antibodies against both HEV and the inserted epitope.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068233      PMCID: PMC3020005          DOI: 10.1128/JVI.00657-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Interpretation of electron density with stereographic roadmap projections.

Authors:  Chuan Xiao; Michael G Rossmann
Journal:  J Struct Biol       Date:  2006-10-24       Impact factor: 2.867

2.  Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay.

Authors:  Suzanne U Emerson; Pilar Clemente-Casares; Nasser Moiduddin; Vidya A Arankalle; Udana Torian; Robert H Purcell
Journal:  J Gen Virol       Date:  2006-03       Impact factor: 3.891

3.  Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus.

Authors:  Tian-Cheng Li; Naokazu Takeda; Tatsuo Miyamura; Yoshiharu Matsuura; Joseph C Y Wang; Helena Engvall; Lena Hammar; Li Xing; R Holland Cheng
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.

Authors:  Yi-Hua Zhou; Robert H Purcell; Suzanne U Emerson
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

5.  Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction.

Authors:  Shaowei Li; Xuhua Tang; J Seetharaman; Chunyan Yang; Ying Gu; Jun Zhang; Hailian Du; J Wai Kuo Shih; Choy-Leong Hew; J Sivaraman; Ningshao Xia
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

Review 6.  Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention.

Authors:  Isa K Mushahwar
Journal:  J Med Virol       Date:  2008-04       Impact factor: 2.327

7.  Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.

Authors:  Tejaswini M Deshmukh; Kavita S Lole; Anuradha S Tripathy; Vidya A Arankalle
Journal:  Vaccine       Date:  2007-04-09       Impact factor: 3.641

8.  Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response.

Authors:  R Bendall; V Ellis; S Ijaz; P Thurairajah; H R Dalton
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

Review 9.  Hepatitis E virus.

Authors:  Mohammad S Khuroo; Mehnaaz S Khuroo
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

10.  Serological evidence of hepatitis E virus infection in an indigenous North American population.

Authors:  G Y Minuk; A Sun; D F Sun; J Uhanova; L E Nicolle; B Larke; A Giulivi
Journal:  Can J Gastroenterol       Date:  2007-07       Impact factor: 3.522

View more
  35 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Chimeric hepatitis E virus-like particle as a carrier for oral-delivery.

Authors:  Pitchanee Jariyapong; Li Xing; Nienke E van Houten; Tian-Cheng Li; Wattana Weerachatyanukul; Benjamin Hsieh; Carlos G Moscoso; Chun-Chieh Chen; Masahiro Niikura; R Holland Cheng
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

3.  In-silico design and molecular docking evaluation of peptides derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of Hepatitis E virus capsid protein.

Authors:  Carolina Quintero-Gil; Jaime Parra-Suescún; Albeiro Lopez-Herrera; Sergio Orduz
Journal:  Virusdisease       Date:  2017-06-09

4.  Structural basis for the neutralization and genotype specificity of hepatitis E virus.

Authors:  Xuhua Tang; Chunyan Yang; Ying Gu; Cuiling Song; Xiao Zhang; Yingbin Wang; Jun Zhang; Choy Leong Hew; Shaowei Li; Ningshao Xia; J Sivaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-03       Impact factor: 11.205

Review 5.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Harry R Dalton; Florence Abravanel; Jacques Izopet
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

6.  Chemically activatable viral capsid functionalized for cancer targeting.

Authors:  Chun-Chieh Chen; Li Xing; Marie Stark; Tingwei Ou; Prasida Holla; Kai Xiao; Shizuo G Kamita; Bruce D Hammock; Kit Lam; R Holland Cheng
Journal:  Nanomedicine (Lond)       Date:  2016-01-20       Impact factor: 5.307

7.  Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods.

Authors:  Chun Chieh Chen; Marie Stark; Mo Baikoghli; R Holland Cheng
Journal:  J Vis Exp       Date:  2018-05-11       Impact factor: 1.355

8.  Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody.

Authors:  Ying Gu; Xuhua Tang; Xiao Zhang; Cuiling Song; Minghua Zheng; Kaihang Wang; Jun Zhang; Mun-Hon Ng; Choy-Leong Hew; Shaowei Li; Ningshao Xia; J Sivaraman
Journal:  Cell Res       Date:  2015-03-20       Impact factor: 25.617

Review 9.  Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery.

Authors:  Marie Stark; R Holland Cheng
Journal:  Pharm Pat Anal       Date:  2016-09

10.  The hepatitis E virus capsid C-terminal region is essential for the viral life cycle: implication for viral genome encapsidation and particle stabilization.

Authors:  Tomoyuki Shiota; Tian-Cheng Li; Sayaka Yoshizaki; Takanobu Kato; Takaji Wakita; Koji Ishii
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.